New combo therapy aims to wipe out hidden myeloma cells

This phase 3 trial tests whether a new drug combination (belantamab mafodotin plus standard drugs) works better than the current standard (daratumumab plus standard drugs) for people newly diagnosed with multiple myeloma who cannot have a bone marrow transplant. The study will enroll 500 participants and look for very low levels of remaining cancer cells (MRD) and longer time without the disease getting worse. Treatment continues until the disease progresses or side effects become unacceptable.